NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/30/2026
Back to search
Official data from USPTO
ANAXIS PHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ANAXIS PHARMA
ST13
US500000079324999Class
42, 45
Filing
79324999
Registration
7014615
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
27
Latest update
07/30/2026
Trademark type
Word
Nice classes
42, 45
Filing date
09/10/2021
Registration date
04/04/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/04/2023
Last transaction
07/30/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
AU
Examiner
KEAN, AMY C
Law office
N30
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Anaxis Pharma Pty Ltd
Representatives
Neil B Friedman Hodgson Russ LLP
Technical classification
Nice Classes
Class 42Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Scientific research and development; Pharmaceutical research and development; Pharmaceutical research advisory and pharmaceutical testing services; Preparation of scientific reports; Scientific researchdesignanalysis and testing of pharmaceutical products; Conducting medical research; Conducting clinical trials for others in the field of pharmaceuticals; Provision of scientific information in the field of pharmaceutical products; Scientific and technical analysis in the field of medical and scientific research and pharmaceutical product research; Scientific research consultancy in the field of pharmaceuticals; Scientific research in the field of pharmacy; Medical research; research and development of products; Research relating to pharmaceuticals; Advisory and consultancy services relating to the aforementioned services
Class 45
Licensing of intellectual property rights; Legal services relating to the exploitation of patent and copyright intellectual property rights; Enforcement of intellectual property rights; Advisory services relating to intellectual property rights; Research relating to intellectual property
Publications
History of USPTO decisions and trademark events.
27 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
08/14/2023
FICS
FINAL DISPOSITION NOTICE SENT TO IB
07/21/2023
FIMP
FINAL DISPOSITION PROCESSED
07/21/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/04/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/04/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
04/04/2023
GPNX
NOTIFICATION PROCESSED BY IB
01/24/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/17/2023
PUBO
PUBLISHED FOR OPPOSITION
01/17/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/04/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
01/04/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/28/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/15/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/02/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/02/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/02/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
08/14/2022
RFNT
REFUSAL PROCESSED BY IB
07/19/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/30/2022
RFRR
REFUSAL PROCESSED BY MPU
06/30/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/16/2022
CNRT
NON-FINAL ACTION WRITTEN
06/15/2022
DOCK
ASSIGNED TO EXAMINER
06/15/2022
MAFR
APPLICATION FILING RECEIPT MAILED
11/12/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/08/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
11/04/2021
Continuous trademark protection
Get notified about every new filing that threatens ANAXIS PHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.